Diffuse Large B-Cell Lymphoma (DLBCL)

Showing 1 - 25 of 31

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)

Completed
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • Lymphodepleting chemotherapy
  • San Francisco, California
  • +25 more
Jan 27, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in China (abexinostat)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Beijing, China
  • +22 more
Jan 26, 2023

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Pembroke Pines, Florida
  • +3 more
Jan 23, 2023

Relapsed or Refractory (R/R) Follicular Lymphoma (FL), DLBCL (DLBCL) Trial (Odronextamab)

Available
  • Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • (no location specified)
Nov 8, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
Oct 23, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • voruciclib monotherapy
  • voruciclib and venetoclax
  • Duarte, California
  • +10 more
Aug 10, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
Jul 14, 2022

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

Completed
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • CAR-T
  • Allo-HSCT cohort
  • East Hanover, New Jersey
    Novartis Investigative Site
Jun 29, 2022

CAR T Cells Real World Evidence Study Based on French Hospital

Completed
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • KYMRIAH
  • YESCARTA
  • East Hanover, New Jersey
    Novartis Investigative Site
Jun 29, 2022

All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,

Active, not recruiting
  • All Malignancies
  • +11 more
  • Encinitas, California
  • +9 more
May 20, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • L19-IL2 - Ph I
  • +2 more
  • Münster, Germany
    Münster University Hospital
Apr 19, 2022

Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL) Trial in United States (rituximab, prednisone, Geriatric

Active, not recruiting
  • Non Hodgkin Lymphoma (NHL)
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Basking Ridge, New Jersey
  • +7 more
Mar 9, 2022

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • +2 more
  • leukapheresis
  • +3 more
  • Omaha, Nebraska
  • +13 more
Jan 21, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL) Trial in Switzerland, United

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Tucson, Arizona
  • +23 more
Dec 14, 2021

Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,

Recruiting
  • Relapsed Large B-cell Lymphoma
  • +5 more
  • CRC01
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
Apr 29, 2021

CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial

Not yet recruiting
  • CD5+ Relapsed/Refractory Hematopoietic Malignancies
  • +5 more
  • CT125A cells
  • Cyclophosphamide, fludarabine
  • (no location specified)
Feb 19, 2021

Study to Evaluate Effectiveness and Safety of Polatuzumab

Unknown status
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Polatuzumab Vedotin-Piiq
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Nov 10, 2020